Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analog therapy have limited therapeutic options ^[1][2][3][24,25,26]. With the exception of everolimus for the treatment of nonfunctional neuroendocrine tumors, no standard second-line systemic treatment options are currently available ^[4][5][27,28]. NETTER-1, a phase 3 trial that was carried out at 41 centers in eight countries across Europe and the USA, allowed for the evaluation of the place of Lutathera® in neuroendocrine tumors in patients aged 18 years and older with advanced, inoperable, well-differentiated (Ki67 index ≤20%) midgut NETs with positive uptake on ¹¹¹In -DTPA octreotide scintigraphy (OctreoScan®) or on [⁶⁸Ga]Ga-DOTATATE/DOTATOC PET-CT on all target lesions and centrally confirmed disease progression on CT or MRI (as per the Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1) while taking a fixed dose of long-acting octreotide 20−30 mg every 3–4 weeks for at least 12 weeks before randomization. Patients had to have a Karnofsky performance status score of at least 60. Previous PRRT was not allowed, nor was any surgery, transarterial therapy, or chemotherapy within 12 weeks of randomization ^[6][7][18,29]. The indication retained in the marketing authorization is the treatment of inoperable, metastatic, progressive, well-differentiated (G1 and G2) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors ^[8][30]. Lutathera® is a second-line treatment after disease progression with octreotide in metastatic, progressive, well-differentiated, somatostatin receptor-expressing intestinal NETs or a third-line treatment after everolimus failure ^{[9][10][11][12][13][14][15][16]}[31,32,33,34,35,36,37,38]. Eligible patients must have had positive imaging with [⁶⁸Ga]Ga -DOTATATE or [⁶⁸Ga]Ga-DOTATOC to confirm somatostatin receptor overexpression. Patient eligibility should also take into account other treatment options as well as factors that may affect the response to treatment (tumor burden, primary tumor site or previous treatments) ^{[17][18][19][20][21][22][23]}[39,40,41,42,43,44,45]. The guidelines published since 2013 ^[13][15][35,37] retain the need for a multidisciplinary meeting (oncologists, nuclear physicians, radiologists, radiopharmacists, surgeons, gastroenterologists, and anatomopathologists) to validate the patient’s eligibility for treatment with [¹⁷⁷Lu]Lu-DOTATATE ^{[18][22][24][25]}[40,44,46,47]. Contraindications to treatment are pregnancy, hypersensitivity to the active substance or to one of the excipients, severe associated disease (severe cardiac, hepatic, or hematological disorders), and severe psychiatric disorders. [¹⁷⁷Lu]Lu-DOTATATE is contraindicated in patients with severe renal impairment and creatinine clearance <30 mL/min. It is not recommended in patients with a creatinine clearance at initiation <40 mL/min ^[8][15][18][30,37,40]. The ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms recommend that patients have a creatinine clearance ≥50mL/min ^[13][18][35,40].

Pluvicto® is indicated for the treatment of adult patients with progressive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen channel blocking hormone therapy and taxane-based chemotherapy ^[26][48].

Pluvicto® was studied as a targeted radioligand therapy (RLT) in an international phase 3 trial named VISION. The VISION trial was a randomized, multicenter, active-control study comparing the best standard of care with or without Pluvicto® ^[27][22].

The study enrolled men with mCRPC that were in progression after one or more approved androgen–receptor-pathway inhibitor therapies and with either one or two taxane regimens. Eligible patients had PSMA-positive metastatic castration-resistant prostate cancer, in other words, at least one PSMA-positive metastatic lesion (PSMA-positive status was determined with the use of Gallium-68 (⁶⁸Ga)–labeled PSMA-11 ([⁶⁸Ga]Ga-PSMA-11) PET–CT imaging at baseline) ^[28][49]. The presence of PSMA-positive lesions was defined in the protocol as a [⁶⁸Ga]Ga-PSMA-11 uptake greater than that of liver parenchyma in one or more metastatic lesions of any size in any organ system. A performance-status score of 0 through 2 (on a scale from 0 to 5, with higher numbers indicating greater disability) ^[29][50], a life expectancy of at least 6 months, and adequate organ and bone marrow function were also required ^{[30][31][32][33][34]}[51,52,53,54,55].

On the day of injection, the patient is placed in a radiation-protected room sealed by the medical staff (nurse, nursing assistant, or nuclear medicine technician). The floor, especially in the bathroom, should be chosen to facilitate cleaning in the case of vomiting or splashes. It is also possible to cover the floor with absorbent sheets in the case of vomiting. Zoning of the room (i.e., a delimitation and signposting of the restricted zones, allowing the danger of exposure to ionizing radiation to be identified) must be carried out by a competent person in charge of radiation protection (Figure 12) ^[35][56]. Patients do not need to fast before treatment.

A fixed dose of 7.4 GBq (200 mCi) of [¹⁷⁷Lu]Lu-DOTATATE is infused intravenously over a period of 30 min. Patients receive four infusions approximately every 8 weeks (cumulative radioactivity, 29.6 GBq [800 mCi]). Reassessment of the clinical and biological status should be routinely undertaken between treatments ^[6][18][36][18,40,57]. Some patients may continue to receive supportive care with long-acting octreotide, administered intramuscularly at a dose of 30 mg approximately 24 h after each infusion of [¹⁷⁷Lu]Lu-DOTATATE, and then monthly after the completion of four courses ^[6][18][36][18,40,57] (Figure 23). A post-therapy whole body scan can be performed 24 h after the injection to check the tumor targeting and to obtain an initial idea of the therapeutic response ^[36][57].

For patients with clinical symptoms (diarrhea and flushing) and/or adverse events (defined as Grade 2 platelet count toxicity, Grades 3 or 4 hematological toxicity other than lymphocytopenia, a 40% increase in serum creatinine from the baseline with a concomitant decrease of more than 40% in creatinine clearance, or any other Grades 3 or 4 toxicity that may be related to the study drug), infusions may be extended for up to 16 weeks to allow for the resolution of acute toxicity. After the resolution of adverse events, 50% of the standard treatment dose (i.e., 3.7 GBq–100 mCi) can be prescribed ^[6][8][18,30] (Table 1).

Short-acting octreotide is not allowed for 24 h before the administration of [¹⁷⁷Lu]Lu-DOTATATE, unless this is clinically impossible. Short-acting octreotide can only be continued if the tumor uptake on SSTR imaging during continued somatostatin analog medication is superior to the liver uptake.

As with Lutathera®, the patient is placed, in the morning, in a radiation protected room or dedicated room with a toilet connected to the radiation decay tanks by medical staff (nurse, nursing assistant or nuclear medicine technician) (Figure 2). Patients do not need to fast before treatment.

The patient receives intravenous infusions of [¹⁷⁷Lu]Lu-PSMA-617 at a dose of 7.4 GBq (200 mCi) once every 6 weeks (± 1 week) up to a maximum of six cycles, unless there is disease progression or unacceptable toxicity ^{[26][27][30][31][37]}[22,48,51,52,58]. In the case of a patient with a serious adverse event, Pluvicto® may be withheld until improvement or the dose may be reduced by 20% to 5.9 GBq (160 mCi). If these effects persist, treatment may be discontinued (Table 2) ^[26][34][37][48,55,58].

Before any injection of Pluvicto® and between doses (approximately every three weeks), a biological and clinical check-up should be performed ^{[26][30][34][37]}[48,51,55,58]. In addition, in non-surgically castrated patients, chemical castration with a gonadotropin-releasing hormone analog should be maintained ^[26][48] Patients do not need to fast before treatment.

Monitoring of the PSA biomarker should be carried out throughout the treatment period. A post-injection scan should be performed to confirm the radiopharmaceutical uptake and therefore the tumor uptake ^[30][34][51,55].

For renal protection, the most commonly used intravenous amino acid solution is one containing 25 g arginine and 25 g lysine, diluted in 1 l of 0.9% NaCl. This infusion is started about 30 min before the Lutathera® infusion and continues for 4 h ^{[23][36][39][40]}[45,57,60,61] (Figure 23). Other infusion protocols exist as well as other commercial solutions of amino acids, but are often more osmolar and therefore more at risk of adverse effects such as nausea and vomiting ^[23][40][41][45,61,62].

To prevent the onset of nausea or vomiting, premedication with antiemetic drugs is administered 30 min before the infusion of the amino acid solution by an intravenous bolus of granisetron (3 mg), ondansetron (8 mg and most commonly used), or tropisetron (5 mg) ^[23][36][40][45,57,61].

The administration of Lutathera and its associated pre-medication requires collaboration between different health care professionals, (e.g., nurses, nursing assistants, and nuclear medicine technicians).

Different methods of administration are reported and the three main ones are presented herein (Figure 34) ^[40][61]. Variations exist but thwe researchers will not dwell on them here. For gravity administration, during the infusion, the flow of the 9 mg/mL (0.9%) sodium chloride infusion solution increases the pressure in the Lutathera® vial, which facilitates the flow of Lutathera® into the catheter inserted in the patient’s peripheral vein. The amino acid solution is passed through another catheter in the patient’s other arm. For the pump and vial method, the pump is set to deliver the volume of [¹⁷⁷Lu]Lu-DOTATATE over 25–30 min. The [¹⁷⁷Lu]Lu-DOTATATE is delivered in 20–25 mL of volume, resulting in an administration rate of 0.8–0.9 mL/min. Then, there is the pump method with a syringe that will be inserted into a syringe guard. At the end of the infusion, the therapy bottle is rinsed with sterile saline solution ^{[8][23][40][42][43]}[30,45,61,63,64]

Prophylactic treatments may include antiemetics (e.g., ondansetron) and corticosteroids (such as dexamethasone). Optional treatments include allopurinol in patients with gout or high tumor burden, cooling of the salivary glands before and/or during administration, and the infusion of 500 mL of 0.9% saline after administration ^{[26][30][34][38]}[48,51,55,59].

[¹⁷⁷Lu]Lu-PSMA-617 is administered slowly by the intravenous route. The infusion is preceded and followed by a saline flush with ≥10 mL of sterile 0.9% sodium chloride administered to ensure patency of the IV line and to minimize the risk of extravasation. Vital signs are monitored 15 min before administration and 30 and 60 min after administration. Patients are encouraged to maintain adequate fluid intake to reduce radiation exposure to the bladder ^[26][30][34][48,51,55].

Pluvicto® is administered intravenously by syringe with a syringe shield (with or without a syringe pump), by gravity infusion (with or without an infusion pump), or by vial infusion (peristaltic infusion pump) (Figure 34). Pluvicto® should not be injected directly into another intravenous solution. If a reduced dose of [¹⁷⁷Lu]Lu-PSMA-617 is available, it should be administered by the syringe or vial method with a peristaltic pump. The gravity method is not recommended as the volume administered may be incorrect ^[26][38][48,59].